Automated cell counters are widely used in modern clinical laboratories to provide reliable, fast, and costeffective complete blood counts (CBCs), white blood cell differentials, and reticulocyte measurements. In addition, some advanced instruments provide novel parameters, such as the hemoglobin content of reticulocytes or the percentage of hypochromic cells, and are capable of analysis of a variety of body fluids. Bayer recently introduced the ADVIA 2120 system as an automation-ready cell counter for mid-to high-volume testing in the clinical laboratory. This instrument, which builds on the established technology of the ADVIA 120 system, operates with a cyanidefree method for hemoglobin measurement, has a new user interface, and can routinely analyze biological fluid samples in addition to blood. We used 749 samples from 6 worldwide trial sites to evaluate the clinical performance of this new device. Accuracy of the ADVIA 2120 system versus its predecessor model, the ADVIA 120 system, was excellent for all CBC and white cell differential parameters and reticulocyte counts (all correlation coefficients except for basophils >0.9). Correlation of the white cell differential with the standard manual method and within-run precision of the ADVIA 2120 system also was very good. Use of the novel cyanide-free method for hemoglobin measurement had no clinically significant impact on hemoglobin results, even in patients with hemoglobinopathies. We concluded that the ADVIA 2120 system has clinically equivalent performance to the ADVIA 120 system.
INTRODUCTION
Complete blood cells counts (CBCs) and white blood cell (WBC) differentials are among the most frequently ordered laboratory tests. Historically these assays were manually performed, labor intensive, and associated with large coefficients of variation. Progress in the design of laboratory instrumentation has made it possible to replace the manual performance of the vast majority of these tests with highly automated assays. These laboratory instruments have been shown to provide reliable clinical results with a much shorter turnaround time, lower cost, and higher reproducibility than the manual approach [1] . In addition, these analyzers can generate a large number of novel parameters that are not achievable through the manual method and are increasingly also used for cell counting in fluids other than blood [2, 3] and even innovative applications such as determination of fetal lung maturity [4] . Such trends continue to dominate the field. Newer models add further automation by a direct interface with a specimen management system and/or a slide maker-stainer, more user-friendly and clinically reliable software components, and increased awareness of environmental concerns.
The ADVIA 120 Hematology System (Bayer HealthCare, Diagnostics Division, Tarrytown, NY, USA) is a well-established modern cell counter for blood and biological fluid analysis that is used in clinical laboratories worldwide. The system has 2 methods of measuring hemoglobin: a modification of the manual cyanmethemoglobin method and a cell-based hemoglobin measurement [5] . Red blood cells and platelets are analyzed on a cell-by-cell basis with 2 angles of light scatter. This innovative method allows reporting of novel parameters, such as percentage of hypochromic red cells [6] and mean platelet component (MPC), and provides increased accuracy in the enumeration of platelets [7] [8] . Myeloperoxidase staining, cell size, and nuclear lobulation are used to obtain a 6-part differential consisting of neutrophils, lymphocytes, monocytes, eosinophils, basophils, and large unstained cells (LUC). Staining with oxazine 750 allows enumeration of reticulocytes and, in combination with light-scatter analysis, reporting of the hemoglobin content of reticulocytes, a US Food and Drug Administrationcleared marker of iron metabolism [9] [10] [11] [12] .
The ADVIA 2120 system was recently introduced as a new hematology analyzer designed for mid-to high-volume testing in the routine clinical laboratory. Building on technology successfully used in the ADVIA 120 model, the ADVIA 2120 system operates with a cyanide-free hemoglobin method [13, 14] , has a new user interface, has more sensitive criteria for the enumeration of blasts and monocytes, is automation ready, and can be used for routine analysis of biological fluid samples in addition to peripheral blood [3] . To assess the analytical performance of this new instrument, we conducted an international multicenter clinical trial comparing its performance with that of the ADVIA 120 system and with results of the National Committee for Clinical Laboratory Standards (NCCLS) reference manual method for WBC differential.
MATERIALS AND METHODS

Study Sites
The study was performed at 6 sites: Johann Gutenberg University Central Laboratory, Mainz, Germany; Laboratorio Analisi Ospedale Civile, Lavagna, Italy; Loma Linda University Hospital, San Bernardino, California, USA; Massachusetts General Hospital, Boston, Massachusetts, USA; University of Florida/Shands Hospital Core Laboratory, Gainesville, Florida, USA; and Core Laboratory, Hospital Clinic, University of Barcelona, Spain.
Instrument Software
The ADVIA 2120 system was run with software version 4.05 with the sensitive flagging option selected for data collection. The ADVIA 120 systems were run with software version 2.2.2a, 3.0.1, or 3.0.12. None of the ADVIA 120 systems had the sensitive flagging software installed.
Manual Differentials (Reference Method)
Manual differentials were performed on blood smears obtained at 5 of the study sites. A total of 593 blood smears were evaluated. For each smear, 2 independent technologists performed a 200-cell WBC differential according to the H-20 NCCLS guidelines [15] .
Study Protocol
The study was performed over 5 days at each site. Instruments were operated by hospital employees trained in the use of the ADVIA 120 and ADVIA 2120 systems. Control materials were assayed, and a 20-sample precision Performance Evaluation of the ADVIA 2120 63 run with whole blood was performed each day at each site. Twenty-five randomly selected patient samples were assayed each day with both the ADVIA 2120 and the ADVIA 120 systems in CBC/Diff mode for a total of 125 samples at each site, for an overall total of 750 samples. One of these samples was removed from analysis because it was a short sample on the ADVIA 120 system. As a result, the sample size for the accuracy study was 749 samples. Of these 749 samples, 575 were also analyzed in reticulocyte mode. A reliability log for the ADVIA 2120 system was kept at each site.
Statistical Analysis
Regression analysis was performed to compare the results between the ADVIA 2120 system, the ADVIA 120 system, and the reference method. Binomial envelopes surrounding the manual counts were also shown for the manual counts, as recommended by NCCLS H-20A [15] .
RESULTS
Accuracy of the ADVIA 2120 System Compared with the ADVIA 120 System Agreement between the ADVIA 2120 and the ADVIA 120 systems for CBC, WBC differential, and reticulocyte counts was determined on 749 samples. Regression analysis results are shown in Table 1 . The x,y regression plots are shown in Figures 1 and 2 . Correlation was excellent for all CBC parameters, all correlation coefficients being higher than 0.97. The correlation for platelet count was excellent even in the clinically crucial low platelet count range (r = 0.969 for platelet counts less than 50,000). Correlation also was very good for the WBC differential and reticulocyte results. Correlation was lowest for the cell types occurring in low numbers (eg, basophils). There was also a slightly lower correlation for monocytes (r = 0.939) than for other differential parameters.
Performance Evaluation of the ADVIA 2120 67 Accuracy of the ADVIA 2120 System versus Manual Differential WBC differential results from 593 samples obtained at 5 sites and determined with the ADVIA 2120 system were compared with 200-cell manual differentials performed by 2 technologists. For the purpose of this comparison, the LUC counts of the ADVIA 2120 system were added to system lymphocyte count and compared with the manual lymphocyte count. Accuracy statistics are shown in Table 2 , and plots of the results are shown in Figure 3 . As for correlation with the ADVIA 120 system, correlation of the automated differential results from the ADVIA 2120 system with the manual counts was very good.
ADVIA 2120 System Within-Run Precision
Results from within-run replicate analysis of blood samples on the ADVIA 2120 system are shown in Tables 3 and  4 . A total of 600 CBCs, white cell differentials, and reticulocyte counts were performed on 30 samples. Results from the 5 runs at each site were pooled to give a summary for each site. Within-run precision for the ADVIA 2120 system was very good and met the ADVIA 120 system specifications. As expected, cell types that occur in lower numbers in peripheral blood had higher coefficients of variation.
Samples from Patients with Hemoglobinopathies
The ADVIA 2120 system operates with a novel cyanidefree method for measurement of hemoglobin level [13] . To ascertain whether this method was reliable for measurement of hemoglobin in patients with congenital hemoglobinopathies, we used the ADVIA 120 system with the standard cyanide-dependent method and the ADVIA 2120 system with the cyanide-free method to analyze samples from patients with sickle cell trait and other structural and quantitative abnormalities of hemoglobin synthesis. No clinically significant difference in hemoglobin levels was found with the 2 methods (Table 5) . 
System Reliability
Two reliability incidents on the ADVIA 2120 system were reported as part of the study. In 1 incident, 2 minutes of downtime were recorded for changing a clot filter. Several clotted samples had been run on the ADVIA 2120 system, and the clot filter was changed as a precautionary measure. In the other incident, a leak was observed in the RBC reagent area when the instrument was set up prior to the study. It was found that the sheath reagent line had disconnected from its reagent pump. No downtime was recorded, because the study had not yet started.
DISCUSSION
We evaluated the accuracy, precision, and reliability of the ADVIA 2120 automated cell counter in an international multicenter clinical trial. Our data indicated very good correlation between CBC, white cell differential, and reticulocyte counts obtained with the ADVIA 2120 system and results obtained with the ADVIA 120 system, an instrument with a well-established clinical track record and years of successful use in a large number of laboratories worldwide. Most correlation coefficients for reported parameters were greater than 0.95. The slightly lower correlation coefficient for monocytes (0.939) was most likely due to the use of new, more sensitive flagging software on the ADVIA 2120 system. In this software, the threshold between monocytes and neutrophils has been changed, leading to slightly (1%) increased recovery of monocytes compared with previous software versions. The lower correlation coefficient for basophils (0.772) was most likely caused by the very low numbers in which these cells occur in blood. An even lower correlation coefficient for basophils was recently reported by Kaplan and co-workers for a different line of cell counters [16] . Correlation of the white cell differentials obtained on the ADVIA 2120 system with results of the reference method, manual 200-cell counts by 2 technologists, was also very good. Within-run precision of the ADVIA 2120 system was comparable with the performance of the ADVIA 120 system.
The ADVIA 2120 system operates with a novel cyanidefree method of measuring hemoglobin. Interference of abnormal hemoglobins with results from automated cell counters has been reported in the literature [17] . We were concerned that abnormal hemoglobins, such as hemoglobin S, E or C, might give different measurements on the ADVIA 2120 system. Our results indicated that at least for the abnormal hemoglobins we investigated, the cyanide-free method gave results clinically equivalent to those obtained with the standard ADVIA 120 method.
In summary, our findings indicated that the performance of the ADVIA 2120 system is clinically equivalent to that of the ADVIA 120 system, its predecessor model. In addition to the proven clinical track record of its predecessor model, the new instrument provides a cyanide-free method of hemoglobin determination, a more user-friendly software interface, a gating system more sensitive to the presence of blasts, the ability to analyze biological fluids as a standard feature, and capability for interface with an automated slide maker-stainer and a laboratory automation system. These features should make this instrument attractive to medium-to high-volume laboratories looking for a modern cell counter capable of providing clinically reliable CBC and differential results as well as novel parameters and fluid analysis, either as a stand-alone system or as part of a laboratory automation system.
